TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.15 CNY | +0.40% |
|
+0.79% | -6.28% |
| Mar. 29 | Dongbao Pharma's 2023 Profit Drops 26% | MT |
| Jan. 29 | Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 3.43B 473M | Sales 2025 * | 3.89B 537M | Capitalization | 20.13B 2.78B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.3B 179M | Net income 2025 * | 1.51B 208M | EV / Sales 2024 * | 5.24 x |
| Net cash position 2024 * | 2.18B 302M | Net cash position 2025 * | 1.87B 258M | EV / Sales 2025 * | 4.7 x |
| P/E ratio 2024 * |
15.6
x | P/E ratio 2025 * |
13.5
x | Employees | 3,196 |
| Yield 2024 * |
2.39% | Yield 2025 * |
2.61% | Free-Float | 59.21% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.40% | ||
| 1 week | +0.79% | ||
| Current month | -0.98% | ||
| 1 month | -2.12% | ||
| 3 months | +1.81% | ||
| 6 months | -7.73% | ||
| Current year | -6.28% |
1 week
9.90
10.29
1 month
9.8211.09
Current year
8.4011.09
1 year
8.4012.73
3 years
8.3513.38
5 years
8.3519.35
10 years
5.3227.51
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Sheng Leng
CEO | Chief Executive Officer | 50 | - |
Feng Qin Li
BRD | Director/Board Member | 64 | - |
Liping Gu
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Ye Wang
CHM | Chairman | 59 | 20-09-27 |
Feng Qin Li
BRD | Director/Board Member | 64 | - |
Ya Ren An
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 12 M€ | -16.71% | - | |
| 0.28% | 2 M€ | -19.84% | - | |
| 0.00% | 34 M€ | +1.04% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 10.15 | +0.40% | 24,698,470 |
| 24-04-17 | 10.11 | +1.71% | 22,716,300 |
| 24-04-16 | 9.94 | -1.19% | 31,532,440 |
| 24-04-15 | 10.06 | +0.30% | 27,744,160 |
| 24-04-12 | 10.03 | -0.40% | 19,631,980 |
End-of-day quote Shanghai S.E., April 17, 2024
More quotes
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company provides biological products, traditional Chinese medicines and chemical supplements, applied in the treatment of diabetes and cardiovascular and cerebrovascular diseases, among others. The Company's main products portfolio consists of recombinant human insulin bulk drugs and injections, zhennaoning capsules, among others. The Company also provides medical instruments, plastic-steel windows and profiles, and operates property business. The Company distributes its products within domestic markets and to overseas markets.
Sector
Pharmaceuticals
Calendar
10:00pm
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.15
CNY
Average target price
15.27
CNY
Spread / Average Target
+50.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.28% | 2.78B | |
| -5.99% | 84.46B | |
| +3.95% | 40.85B | |
| -26.37% | 27.69B | |
| +50.19% | 24.28B | |
| -6.59% | 17.09B | |
| -32.37% | 13.67B | |
| -10.45% | 11.79B | |
| -15.88% | 11.86B | |
| -3.97% | 8.07B |
- Stock Market
- Equities
- 600867 Stock
